Anecdotal, declares Kaiser Fauci. Next.
HCQ does not benefit Gilead. It cheap to provide and administer.
Simple as that.
NB: A majority of the NIH “independent” Data and Safety Monitoring Board member have or have been funded by or otherwise connected with Gilead.
Also, Remdesivir’s survival benefit has a p-value of 0.059. For studies such as this, the p-value must be 0.050 or lower to be statistically significant.
But Remdesivir is a Gilead patented product, and each course of treatment will cost thousands.
Fauci must be a witch doctor. . . .